The beneficial effect of combining anti-DLL4 and bispecific anti-DLL4/VEGF antibody with irinotecan was further confirmed in xenograft and orthotopic mouse models of gastric cancer and colon cancer [236,538]. This evidence concerns the gene DLL4 and gastric cancer.